PA
PTCT icon

Profund Advisors’s PTC Therapeutics PTCT Stock Holding History

Profund Advisors’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.27M Buy
33,326
+1,473
+5% +$104K 0.08% 175
2025
Q4 		$2.42M Buy
31,853
+9,591
+43% +$697K 0.07% 177
2025
Q3 		$1.37M Buy
22,262
+1,420
+7% +$74K 0.04% 264
2025
Q2 		$1.02M Buy
20,842
+8,131
+64% +$386K 0.04% 299
2025
Q1 		$648K Sell
12,711
-3,325
-21% -$166K 0.03% 405
2024
Q4 		$724K Sell
16,036
-4,710
-23% -$202K 0.03% 369
2024
Q3 		$770K Buy
20,746
+1,388
+7% +$46.5K 0.03% 390
2024
Q2 		$592K Sell
19,358
-26,787
-58% -$868K 0.02% 451
2024
Q1 		$1.34M Sell
46,145
-9,233
-17% -$259K 0.05% 275
2023
Q4 		$1.53M Buy
55,378
+20,002
+57% +$457K 0.07% 241
2023
Q3 		$793K Sell
35,376
-337
-0.9% -$12.5K 0.04% 339
2023
Q2 		$1.45M Buy
35,713
+6,392
+22% +$313K 0.08% 221
2023
Q1 		$1.42M Buy
+29,321
New +$1.34M 0.09% 195

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Profund Advisors's PTCT Position: Q1 2026 in Review

Profund Advisors increased its PTC Therapeutics (PTCT) stake by 4.6% in Q1 2026, buying an estimated $104K and bringing the position to 33,326 shares worth $2.27M. The position accounts for 0.08% of the portfolio, ranked #175.

Profund Advisors first reported a position in PTCT in Q1 2023 and has held it in 13 quarters since. The position peaked at $2.42M in Q4 2025. 349 funds tracked by Wall St. Rank hold PTCT as of Q1 2026.

  • Profund Advisors held 33,326 shares of PTC Therapeutics worth $2.27M as of Q1 2026.
  • Profund Advisors bought 1,473 PTC Therapeutics shares in Q1 2026, an estimated $104K.
  • PTC Therapeutics made up 0.08% of Profund Advisors's portfolio in Q1 2026, its #175 holding.
  • Profund Advisors first reported a position in PTC Therapeutics in Q1 2023 and has held it in 13 quarters since.
  • Profund Advisors's PTC Therapeutics position peaked at $2.42M in Q4 2025.
  • 349 funds tracked by Wall St. Rank held PTC Therapeutics as of Q1 2026.

Based on Profund Advisors's 13F filing for Q1 2026, filed 27 Apr 2026.